By Nigam Arora & Dr. Natasha Arora Weekly Digest from The Arora Report is popular among serious investors and money managers because they have found studying insights from the prior week gives them an edge over the coming weeks. Here is the day by day rundown from the morning capsules
By Nigam Arora & Dr. Natasha Arora To gain an edge, this is what you need to know today. Hotter Jobs Report Please click here for a chart of S&P 500 ETF (SPY) which represents the benchmark stock market index S&P 500 (SPX). Note the following: The chart shows there is buying
By Nigam Arora & Dr. Natasha Arora To gain an edge, this is what you need to know now. Selloff In Stocks On Common Sense Talk Please click here for a chart of Dow Jones Industrial Average ETF (DIA). Note the following: As we have been sharing with you this stock market
Maravai LifeSciences (MRVI) is long from $25.84. MRVI is trading at $42.25 as of this writing. This represents a gain of 63% in a short time. MRVI reported earnings significantly better than the consensus. We have previously written that the target zone was likely to be raised. MRVI supplies a key
Coronavirus is providing opportunities for investors beyond well-known names. A good example is a stock that most investors have never heard of but have provided 38% return to The Arora Report subscribers in a short time. More gains are likely ahead. The following post was published earlier on ZYX Buy.
Weekly Digest from The Arora Report is popular among serious investors and money managers because they have found studying insights from the prior week gives them an edge over the coming weeks. Here is the day by day rundown from the morning capsules made available every morning before the market
Maravai LifeSciences (MRVI) supplies a key component of the coronavirus vaccine produced by Pfizer (PFE) and BioNTech (BNTX). The vaccine should provide a sharp increase in revenue. The company also has a diversified product portfolio. Zones For those following the Good Way, the Buy Now rating is ‘YES.’ For those
Weekly Digest from The Arora Report is popular among serious investors and money managers because they have found studying insights from the prior week gives them an edge over the coming weeks. Here is the day by day rundown from the morning capsules made available every morning before the market
The big news is that the vaccine from Pfizer (PFE) and BioNTech (BNTX) has been approved in the U. K. The vaccine is providing many long term investment opportunities and many short term trading opportunities. The Chart Please click here for a chart of vaccine maker Moderna (MRNA). Note the
Weekly Digest from The Arora Report is popular among serious investors and money managers because they have found studying insights from the prior week gives them an edge over the coming weeks. Here is the day by day rundown from the morning capsules made available every morning before the market